Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus

Abstract

Erenumab is the first human monoclonal antibody to be approved as a selective therapy for migraine prophylaxis in adults. This study assessed, in a real-world setting, the efficacy of erenumab and its impact on the quality of life (QoL) of Cypriot migraine patients who had failed several treatments in the past. Erenumab was prescribed as a stand-alone or as an add-on therapy to 16 patients with chronic migraine. The first component of the study examined migraine parameters before and after erenumab therapy and included an interim 3-month subjective assessment. In the second component, the patients were asked to complete the validated Migraine-Specific Quality-of-Life Questionnaire—Version 2.1 (MSQ V2.1) during the last month of their individual treatment as a measure of the QoL. The results showed a statistically significant improvement in almost all migraine parameters following erenumab treatment. In the 3-month-interval assessment, 81.3% of the patients reported an improvement in their mental well-being, anxiety, and depression levels, with more than 80% of the patients reporting an improvement in almost all assessed migraine parameters. MSQ V2.1 indicated a good health status in all three domains (mean values > 60 on a scale 0–100), with the “role function preventative” domain having the highest health scores (85). Over a period of 6 months, erenumab was safe, well-tolerated, and effective in preventing migraine symptoms and improving HR-QoL. We conclude that this novel medication, which is not yet part of the national formulary in Cyprus, may be a cost-effective solution in reducing the disease burden of chronic migraine.

Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

“…Emerging literature on patients with migraine treated with erenumab and other CGRP monoclonal antibodies outside of clinical trials has demonstrated improved outcomes for a significant proportion of cases [ 17 – 20 ]. We audited 17–30 months of PROM/QoL data in our cohort of treatment/medically resistant or difficult to treat CM patients to give us insight into the more medium to long-term benefits of anti-CGRP intervention in this type of patient population.…”

“…Emerging literature on patients with migraine treated with erenumab and other CGRP monoclonal antibodies outside of clinical trials has demonstrated improved outcomes for a significant proportion of cases [17][18][19][20]. We Persistence with preventive treatments in migraine in the medium to long term (1-3 years) is a good combined measure of efficacy and side effects.…”

Two Sides of the Same Coin: Fluid Intelligence and Crystallized Intelligence as Cognitive Reserve Predictors of Social Cognition and Executive Functions Among Vulnerable Elderly People

“…However, given the difficulty of access, and despite the small number of participants, it was still possible to robustly demonstrate the expected effects. In favor of this argument, other research types have been published with sample sizes similar to the present study (76)(77)(78). On the other hand, social adaptation was also considered through the protocol study that considered inclusion criteria associated with a population normally adapted to daily life.…”

Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review

“…A prospective observational cohort study assessing the effect of erenumab on efficacy and quality of life parameters (mental well-being, anxiety, and depression levels) examined with the validated Migraine-Specific Quality-of-Life Questionnaire—Version 2.1 (MSQ V2.1) concluded that in the 3-month-interval treatment period, 81.3% of the patients reported an improvement in the examined parameters [ 85 ].…”